Sandbox Reserved 1482: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 99: | Line 99: | ||
Nowadays, recombinant coagulation factor VIII products are developed in labs through the use of DNA technology <ref name="El" /><ref name="toole" />. For instance, Toole and colleagues have created a biologically fully active factor with improved heterologous expression efficiency by deleting the B-domain from the native human factor VIII <ref name="toole" />. | Nowadays, recombinant coagulation factor VIII products are developed in labs through the use of DNA technology <ref name="El" /><ref name="toole" />. For instance, Toole and colleagues have created a biologically fully active factor with improved heterologous expression efficiency by deleting the B-domain from the native human factor VIII <ref name="toole" />. | ||
</StructureSection> | </StructureSection> | ||
